BENEFITS Triple receptor activation studied for simultaneous GLP-1, GIP, and glucagon engagement Metabolic research explored in Phase 2 clinical trials with notable body-composition results Glucagon component linked to thermogenesis and energy-expenditure pathways Next-generation compound investigated as an advancement over dual-agonist approaches Comparative pharmacology assessed alongside mono- and dual-agonists in research settings WHAT RESEARCHERS LOOK AT Triple-agonist binding affinity across GLP-1, GIP, and glucagon receptors Additive effects of glucagon-receptor activation on energy expenditure Dose-response and tolerability profiling from clinical-trial data Comparative outcomes vs tirzepatide and semaglutide Pharmacokinetic profiling and receptor selectivity QUICK SPECS Form: Lyophilized peptide powder Net per vial: 10 mg Purity: 99% (HPLC verified) Identity: MS-verified (per COA) Storage: 28C, protect from light and moisture Reconstitution: Use bacteriostatic water (sold separately) IDENTITY BASICS CAS: 2381089-83-2 Classification: Triple GLP-1/GIP/glucagon receptor agonist WHY CHOOSE DURHAM PEPTIDES FOR RETATRUTIDE

It is the center point of the batterys energy profile
A beautiful and healthy body
With most of the surgeries we perform, there is usually very little discomfort afterward
Enrolled patients self-administered a semaglutide injection each week and escalated doses until they reached a 1 mg dose on the fourth week
CH functionality is adaptable, enabling improvements to its unique features ( 2 group influences CH immersion in acidic conditions, with a pK a value of 6.5, reportedly demonstrated (Chattopadhyay and Inamdar, 2010)